Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction

IF 10.3 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
{"title":"Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction","authors":"","doi":"10.1016/j.jchf.2024.03.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, percutaneous coronary intervention (PCI) did not reduce the incidence of death or hospitalization for heart failure (HHF).</p></div><div><h3>Objectives</h3><p>This prespecified secondary analysis investigated the effect of PCI on health status measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) combined with the primary outcome in a win ratio.</p></div><div><h3>Methods</h3><p>Participants with severe ischemic left ventricular dysfunction were randomized to either PCI in addition to optimal medical therapy (OMT) (PCI) or OMT alone (OMT). The primary outcome was a hierarchical composite of all-cause death, HHF, and KCCQ–Overall Summary Score (OSS) at 24 months analyzed using the unmatched win ratio. The key secondary endpoint was a KCCQ-OSS responder analysis.</p></div><div><h3>Results</h3><p>A total of 347 participants were randomized to PCI and 353 to OMT. Median age was 70.0 years (Q1-Q3: 63.3-76.1 years). Mean left ventricular ejection fraction was 27.0 ± 6.7%. PCI did not improve the primary endpoint (win ratio for PCI vs OMT: 1.05; 95% CI: 0.88-1.26; <em>P =</em> 0.58). PCI resulted in more KCCQ-OSS responders than OMT at 6 months (54.1% vs 40.7%; OR: 1.96; 95% CI: 1.41-2.71; <em>P &lt;</em> 0.001) and fewer deteriorators (25.2% vs 31.4%; OR: 0.69; 95% CI: 0.47-1.00; <em>P =</em> 0.048). PCI did not impact KCCQ-OSS responders or deteriorators at 12 or 24 months.</p></div><div><h3>Conclusions</h3><p>PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up. (Revacularization for Ischemic Ventricular Dysfunction [REVIVED-BCIS2]; <span><span>NCT01920048</span><svg><path></path></svg></span>)</p></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 9","pages":"Pages 1553-1562"},"PeriodicalIF":10.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213177924002646/pdfft?md5=599992f76d6c9bef61a09ab764c3cd1e&pid=1-s2.0-S2213177924002646-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Heart failure","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213177924002646","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, percutaneous coronary intervention (PCI) did not reduce the incidence of death or hospitalization for heart failure (HHF).

Objectives

This prespecified secondary analysis investigated the effect of PCI on health status measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) combined with the primary outcome in a win ratio.

Methods

Participants with severe ischemic left ventricular dysfunction were randomized to either PCI in addition to optimal medical therapy (OMT) (PCI) or OMT alone (OMT). The primary outcome was a hierarchical composite of all-cause death, HHF, and KCCQ–Overall Summary Score (OSS) at 24 months analyzed using the unmatched win ratio. The key secondary endpoint was a KCCQ-OSS responder analysis.

Results

A total of 347 participants were randomized to PCI and 353 to OMT. Median age was 70.0 years (Q1-Q3: 63.3-76.1 years). Mean left ventricular ejection fraction was 27.0 ± 6.7%. PCI did not improve the primary endpoint (win ratio for PCI vs OMT: 1.05; 95% CI: 0.88-1.26; P = 0.58). PCI resulted in more KCCQ-OSS responders than OMT at 6 months (54.1% vs 40.7%; OR: 1.96; 95% CI: 1.41-2.71; P < 0.001) and fewer deteriorators (25.2% vs 31.4%; OR: 0.69; 95% CI: 0.47-1.00; P = 0.048). PCI did not impact KCCQ-OSS responders or deteriorators at 12 or 24 months.

Conclusions

PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up. (Revacularization for Ischemic Ventricular Dysfunction [REVIVED-BCIS2]; NCT01920048)

Abstract Image

PCI 对缺血性左心室功能障碍患者健康状况的影响:REVIVED-BCIS2 的启示
在 REVIVED-BCIS2(缺血性心室功能障碍的血管重建)试验中,经皮冠状动脉介入治疗(PCI)并没有降低心衰(HHF)的死亡或住院率。这项预先指定的二次分析调查了PCI对健康状况的影响,健康状况通过堪萨斯城心肌病问卷(KCCQ)测量,并结合主要结果进行胜率分析。患有严重缺血性左心室功能障碍的参与者被随机分配到在最佳药物治疗(OMT)基础上进行 PCI(PCI)或仅进行 OMT(OMT)。主要结局是24个月时全因死亡、HHF和KCCQ-综合评分(OSS)的分层复合结果,采用非匹配胜率进行分析。关键的次要终点是 KCCQ-OSS 应答者分析。共有 347 名参与者随机接受 PCI 治疗,353 名参与者随机接受 OMT 治疗。中位年龄为 70.0 岁(Q1-Q3:63.3-76.1 岁)。平均左心室射血分数为 27.0 ± 6.7%。PCI 并未改善主要终点(PCI vs OMT 的获胜比:1.05;95% CI:0.88-1.26;0.58)。在 6 个月时,PCI 比 OMT 有更多的 KCCQ-OSS 应答者(55.7% vs 41.0%;OR:1.96;95% CI:1.41-2.71;0.001),恶化者较少(23.9% vs 31.2%;OR:0.69;95% CI:0.47-1.00;0.048)。在12个月或24个月时,PCI对KCCQ-OSS应答者或病情恶化者没有影响。在 2 年时,PCI 并未改善死亡、HHF 和健康状况的分层复合指标。在 6 个月时,PCI 改善了 KCCQ-OSS,但在 1 年或 2 年的随访中,这种益处并未持续。(经皮冠状动脉介入治疗改善心衰患者生存率的有效性和安全性研究[REVIVED-BCIS2];)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JACC. Heart failure
JACC. Heart failure CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
21.20
自引率
2.30%
发文量
164
期刊介绍: JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信